scholarly journals Treatment selection for patients with metastatic renal cell carcinoma

Cancer ◽  
2009 ◽  
Vol 115 (S10) ◽  
pp. 2327-2333 ◽  
Author(s):  
Michael B. Atkins ◽  
Toni K. Choueiri ◽  
Daniel Cho ◽  
Meredith Regan ◽  
Sabina Signoretti
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Treatment Selection ◽  
Selection For

scholarly journals Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options

2019 ◽  
Vol 15 (S10) ◽  
pp. 3-10 ◽  
Author(s):  
Andrew Schmidt ◽  
Arun Azad ◽  
Jeffrey Goh ◽  
Carole Harris ◽  
Anthony M. Joshua ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Treatment Selection ◽  
First Line ◽  
Therapy Options ◽  
New Therapy ◽  
Selection For

scholarly journals Personalized Management of Advanced Kidney Cancer

2018 ◽  
pp. 330-341 ◽  
Author(s):  
Jeffrey Graham ◽  
Daniel Y. C. Heng ◽  
James Brugarolas ◽  
Ulka Vaishampayan
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Kidney Cancer ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Biomarkers ◽  
Treatment Selection ◽  
Great Success ◽  
Personalized Care ◽  
Oncogenic Pathways

The treatment of renal cell carcinoma represents one of the great success stories in translational cancer research, with the development of novel therapies targeting key oncogenic pathways. These include drugs that target the VEGF and mTOR pathways, as well as novel immuno-oncology agents. Despite the therapeutic advancements, there is a paucity of well-validated prognostic and predictive biomarkers in advanced kidney cancer. With a number of highly effective therapies available across multiple lines, it will become increasingly important to develop a more tailored approach to treatment selection. Prognostic clinical models, such the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, are routinely used for prognostication in clinical practice. The IMDC model has demonstrated a predictive capability in the context of these treatments including immune checkpoint inhibition. A number of promising molecular markers and gene expression signatures are being explored as prognostic and predictive biomarkers, but none are ready to be widely used for treatment selection. In this review, we will explore the current landscape of personalized care in metastatic renal cell carcinoma. This will include a focus on both prognostic and predictive factors as well as clinical applications of biology in kidney cancer.

Sign in / Sign up

Export Citation Format

Share Document